Dear Colleagues, As the 2020 pandemic has altered our behavioral, economic, educational policies, and numerous other career and life events worldwide, SARS-CoV-2 has also impacted global healthcare and patient outcomes. Fortunately, and not unexpectedly, frontline and advanced line healthcare workers, researchers, and scientists have never ceased the tradition of tireless sacrifice and dedication to advancing patient care. Assuredly we have reviewed and read exceptional cancer care advancements in 2020, including innovative efforts for delivering care via ambulatory processes or through virtual technologies while prioritizing our most vulnerable patient populations. Fortunately, numerous diagnostic and therapeutic advancements in 2020 have occurred in Genitourinary Oncology.
While safeguarding both patients and the healthcare team from unnecessary risk of SARS-CoV-2, telehealth technology and its widespread adoption among healthcare practitioners and patients have allowed for innovative patient care strategies. Virtual education has also persevered and improved during this year of in-person and travel adversity.
Alicia Morgans, MD, MPH Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts. She is a clinician and physician investigator specializing in investigating complications of systemic therapy for prostate cancer survivors. She has expertise in clinical trials and patient-reported outcome measures, and as well as incorporating patient preferences and beliefs into clinical decision making.
DISCLAIMER: The statements and opinions contained in the articles of Everyday Urology®-Oncology Insights are solely those of the authors and contributors. The appearance of the advertisements in the publication is not a warranty, endorsement or approval of the products or services advertised or their effectiveness, quality or safety. The content of the publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing informationfor full disclosure of approved uses. To the extent permissible under applicable laws, no responsibility is assumed by the publisher for any injury and/or damage as a result of any actual or alleged libelous statements, infringement of intellectual property, or privacy rights, or products liability whether resulting from negligence or otherwise, or for any use of operation, ideas, instructions, procedures, products, or methods contained within the material.
Everyday Urology®-Oncology Insights (ISSN 2473-3784) is published four times a year by Digital Science Press, Inc., business office located at 548 Market St #41552, San Francisco, CA 94104-5401
POSTMASTER: Send address changes to Everyday Urology®-Oncology Insights Digital Science Press, Inc. Subscription Customer Service, 548 Market St #41552, San Francisco, CA 94104-5401
Customer service: Customer service inquiries should be sent to publisher@urotoday.com Subscription inquiries should be sent to: cleonard@urotoday.com Access to this journal is online at www.urotoday.com Other correspondence for Digital Science Press, Inc. should be sent to: Attention: Digital Science Press, Inc. 548 Market St #41552, San Francisco, CA 94104-5401
COPYRIGHT AND PERMISSIONS: Everyday Urology®-Oncology Insights is published four times a year by Digital Science Press. No portion of the work(s) can be reproduced without written consent from the Publisher. Permission may be requested directly from the Publisher Email: publisher@urotoday.com ©Copyright 2019.
